Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.
Clinical Trials Arena on MSN
Incyte reports positive data from tafasitamab phase III trial for DLBCL
Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...
Incyte today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback